The U.S. biotech company’s technology will be used to inhibit a target identified by Novartis researchers, the Swiss company said Thursday, without disclosing financial details.
Alnylam, which turned a Nobel Prize-winning concept called RNA interference into treatments for rare genetic conditions, has been a subject of takeover speculation. Novartis, having just sold a $21 billion stake in rival Roche Holding AG, could use the cash to buy a biotech and Alnylam has been on the potential ...